Home > Insider Trading > Filing (0001209191-17-047716)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
875320	Vertex Pharmaceuticals Inc / Ma	VRTX	Pharmaceutical Preparations (2834)	043039129

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1610876	Jeffrey Chodakewitz	C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210	Evp Gmda, Cmo	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2017-08-02	1,796	$91.05	116,220	No	4	M	Direct
Common Stock	Disposition	2017-08-02	500	$152.50	115,720	No	4	S	Direct
Common Stock	Disposition	2017-08-02	600	$153.93	115,120	No	4	S	Direct
Common Stock	Disposition	2017-08-02	400	$154.89	114,720	No	4	S	Direct
Common Stock	Disposition	2017-08-02	296	$156.24	114,424	No	4	S	Direct
Common Stock	Acquisiton	2017-08-03	3,594	$109.14	118,018	No	4	M	Direct
Common Stock	Disposition	2017-08-03	600	$153.29	117,418	No	4	S	Direct
Common Stock	Disposition	2017-08-03	2,494	$154.21	114,924	No	4	S	Direct
Common Stock	Disposition	2017-08-03	500	$155.15	114,424	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2017-08-02	1,796	$0.00	1,796	$91.05
Common Stock	Stock Option (Right to Buy)	Disposition	2017-08-03	3,594	$0.00	3,594	$109.14

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
17,960		2026-02-01	No	4	M	Direct
21,563		2025-02-02	No	4	M	Direct

Footnotes

Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1.
Open market sales reported on this line occurred at a weighted average price of $152.50 (range $152.00 to $152.88).
Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $153.93 (range $153.31 to $154.30).
Open market sales reported on this line occurred at a weighted average price of $154.89 (range $154.70 to $155.40).
Open market sales reported on this line occurred at a weighted average price of $156.24 (range $155.94 to $156.40).
Open market sales reported on this line occurred at a weighted average price of $153.29 (range $152.63 to $153.55).
Open market sales reported on this line occurred at a weighted average price of $154.21 (range $153.71 to $154.64).
Open market sales reported on this line occurred at a weighted average price of $155.15 (range $154.73 to $155.53).
The option vests in 16 quarterly installments from 2/2/2016.
The option vests in 16 quarterly installments from 2/3/2015.